Real-World Effectiveness and Tolerability of Rimegepant as Second- or Third-Line Acute Treatment for Migraine: A Prospective Observational Study. (PubMed, Neurol Ther) - Oct 23, 2026 - "Rimegepant was associated with clinically meaningful pain relief and favorable patient-reported outcomes when used as a second- or third-line acute treatment in real-world clinical practice."
Journal • Observational data • Real-world evidence • CNS Disorders • Migraine • Pain
|
|
Ryuta Saito; Satoshi Shinoda; Satoshi Yamashita; Shinsuke Muraoka; Shun Yamamoto; Takafumi Tanei; Takahiro Suzuki; Tomotaka Ishizaki; Toshihiko Wakabayashi
|